Poor Response to Direct-Acting Antiviral Therapy in HCV-Infected Elderly Population: A Real-Life Cohort Study Based on GeneXpert^® Technology

References

• Razavi H , ElKhouryAC, ElbashaEet al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States . Hepatology57 ( 6 ), 2164 – 2170 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mohamed AA , ElbedewyTA, El-SerafyM, El-ToukhyN, AhmedW, Ali El DinZ . Hepatitis C virus: a global view . World J. Hepatol.7 ( 26 ), 2676 – 2680 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mangia A , CascavillaI, LezziG, SpiritoFet al. HCV genotypes in patients with liver disease of different stages and severity . J. Hepatol.26 ( 6 ), 1173 – 1178 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Brown RS . Hepatitis C and liver transplantation . Nature436 ( 7053 ), 973 – 978 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Messina JP , HumphreysI, FlaxmanAet al. Global distribution and prevalence of hepatitis C virus genotypes . Hepatology61 ( 1 ), 77 – 87 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Parkash O , HamidS . Next big threat for Pakistan hepatocellular carcinoma (HCC) . JPMA66 ( 6 ), 735 ( 2016 ).
   Google Scholar
• Ali M , IdreesM, AliL, HussainAet al. Hepatitis B virus in Pakistan: a systematic review of prevalence, risk factors, awareness status and genotypes . Virology8 ( 1 ), 102 ( 2011 ).
   Google Scholar
• World Health Organization . Hepatitis C ( 2017 ). www.who.int/mediacentre/factsheets/fs164/en/
   Google Scholar
• Palumbo E . Pegylated interferon and ribavirin treatment for hepatitis C virus infection . Ther. Adv. Chronic Dis.2 ( 1 ), 39 – 45 ( 2011 ).
   PubMedGoogle Scholar
• Kemmer N , NeffGW . Managing chronic hepatitis C in the difficult-to-treat patient . Liver Int.27 ( 10 ), 1297 – 1310 ( 2011 ).
   Google Scholar
• Manns M , WedemeyerH, CornbergM . Treating viral hepatitis C: efficacy, side effects, and complications . Gut55 ( 9 ), 1350 – 1359 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Zeuzem S , BergT, MoellerBet al. Expert opinion on the treatment of patients with chronic hepatitis C . J. Viral Hep.16 ( 2 ), 75 – 90 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Navaneethan U , KemmerN, NeffGW . Review: predicting the probable outcome of treatment in HCV patients . Ther. Ad. Gastroenterol.2 ( 5 ), 287 – 302 ( 2009 ).
   PubMedGoogle Scholar
• Zhu Y , ChenS . Antiviral treatment of hepatitis C virus infection and factors affecting efficacy . World J. Gastroenterol.19 ( 47 ), 8963 – 8973 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Wahid B , SaleemK, AliA, RafiqueS, IdreesM . Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience . Eur. J. Gastroenterol. Hepatol.29 ( 8 ), 979 – 980 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Snyder HS , AliB, GonzalezHC, NairS, SatapathySK . Efficacy and safety of sofosbuvir-based H acting antivirals for hepatitis C in septuagenarians and octogenarians . J. Clin. Exp. Hepatol.7 ( 2 ), 93 – 96 ( 2017 ).
   PubMedGoogle Scholar
• Saab S , ParkSH, MizokamiMet al. Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older . Hepatology63 ( 4 ), 1112 – 1119 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Jacobson IM , GordonSC, KowdleyKVet al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options . NEJM368 ( 20 ), 1867 – 1877 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lawitz E , MangiaA, WylesDet al. Sofosbuvir for previously untreated chronic hepatitis C infection . NEJM368 ( 20 ), 1878 – 1887 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Foster GR , AfdhalN, RobertsSKet al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection . NEJM373 ( 27 ), 2608 – 2617 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bourlière M , GordonSC, FlammSLet al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection . NEJM376 ( 22 ), 2134 – 2146 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Lawitz E , SulkowskiMS, GhalibRet al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study . Lancet384 ( 9956 ), 1756 – 1765 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pearlman BL , EhlebenC, PerrysM . The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C–related child’s class A cirrhosis . Gastroenterology148 ( 4 ), 762 – 700 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mandorfer M , KozbialK, FreissmuthCet al. Interferon-free regimens for chronic hepatitis C overcome the effects of portal hypertension on virological responses . Aliment Pharmacol. Ther.42 ( 6 ), 707 – 718 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ahn S , LimY, LeeK, PaikSet al. A Phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 Hepatitis C virus . J. Viral Hep.23 ( 5 ), 358 – 365 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Sarwar S , KhanAA . Sofosbuvir based therapy in Hepatitis C patients with and without cirrhosis: Is there difference?PJMS33 ( 1 ), 37 ( 2017 ).
   Google Scholar
• Kumada H , SuzukiY, IkedaKet al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection . Hepatology59 ( 6 ), 2083 – 2091 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Jacobson IM , KwoPY, KowdleyKVet al. Virologic response rates to all oral fixed-dose combination ledipasvir/sofosbuvir regimens are similar in patients with and without traditional negative predictive factors in Phase 3 clinical trials . Hepatology60, 1141A - 1142A ( 2014 ).
   Web of Science ®Google Scholar
• Kowdley KV , GordonSC, ReddyKRet al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis . NEJM370 ( 20 ), 1879 – 1888 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fried MW , Di BisceglieAM, VierlingJMet al. Safety of ABT-450/r/ombitasvir+ dasabuvir with or without ribavirin in HCV genotype 1-infected patients: results from Phase 2 and Phase 3 trials . Hepatology60, 1145A ( 2014 ).
   Google Scholar
• Kowdley KV , LawitzE, PoordadFet al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1 . NEJM370 ( 3 ), 222 – 232 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bräu N , BiniE, CurrieS, ShenHet al. Black patients with chronic hepatitis C have a lower sustained viral response rate than nonBlacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin . J. Viral Hep.13 ( 4 ), 242 – 249 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Vutien P , HoangJ, BrooksLJr, NguyenNH, NguyenMH . Racial disparities in treatment rates for chronic hepatitis C: analysis of a population-based cohort of 73,665 patients in the United States . Medicine (Baltimore)95 ( 22 ), e3719 ( 2016 ).
   PubMed Web of Science ®Google Scholar